NAFLD Inpatient Stays Surge 88% as Awareness Lags

Event summary

  • AHRQ's first report on NAFLD (now MASLD) reveals an 88.1% increase in related inpatient stays from 2016 to 2022.
  • NAFLD-related inpatient stays represent a small fraction (1-2%) of total stays.
  • The rise in stays is primarily driven by NAFLD being a secondary diagnosis, often linked to conditions like septicemia and obesity.
  • Approximately 1 in 4 Americans are estimated to have MASLD, with 1.5-6.5% having the more severe MASH.
  • The report assesses costs associated with NAFLD and the potential impact of untreated progression to MASH.

The big picture

The AHRQ report highlights a growing public health challenge with significant cost implications. The fact that NAFLD/MASLD is often a secondary diagnosis underscores a broader issue of undiagnosed chronic conditions contributing to hospitalizations. This report provides a baseline for tracking the impact of emerging therapies and preventative measures, and will likely shape future healthcare policy and investment decisions in the space.

What we're watching

Regulatory Scrutiny
The AHRQ report's findings will likely increase pressure on pharmaceutical companies and diagnostic firms to develop and market effective treatments and screening tools for MASLD/MASH, potentially accelerating R&D investment and competition.
Diagnostic Adoption
The relatively low awareness and diagnosis rates suggest that broader adoption of screening and diagnostic tools will be crucial to managing the condition's progression and reducing long-term healthcare costs, impacting diagnostic companies.
Policy Response
The report’s data on costs and prevalence may spur further legislative action and government funding for research and patient support programs, influencing reimbursement models and access to care.

Related topics

Public Health